{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-108467","form_type":"8-K","ticker":"BRTX","cik":"0001505497","company_name":"BioRestorative Therapies, Inc.","filed_at":"2026-10-09T20:05:40+00:00","discovered_at":"2026-10-09T20:07:01.221281+00:00","generated_at":"2026-10-12T15:11:44.946217+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"BioRestorative Therapies appoints Donald J. Currie as Class I director, filling Katharyn Field vacancy","bullets":["Currie, 65, appointed effective Oct 7, 2026, to serve until the 2027 annual meeting; fills the vacancy from Katharyn Field's resignation effective Aug 31, 2026.","Board deemed Currie independent under Nasdaq listing rules and Exchange Act Rule 10A-3; he joins the Compensation and Nominating & Corporate Governance Committees.","Compensation: CAD $2,000 per month cash fee payable in arrears plus expense reimbursement; he will not participate in the standard non-employee director compensation program.","Currie has served as CEO and a director of Hillcrest Energy Technologies (CSE: HEAT; OTCQB: HLRTF) since February 2010, with 30+ years in energy and public-company financing.","No arrangement or understanding with any other person regarding the appointment; no family relationships with directors or officers and no Item 404(a) reportable transactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-108467","json":"https://secwatch.observer/filing/0001213900-26-108467.json","markdown":"https://secwatch.observer/filing/0001213900-26-108467.md","text":"https://secwatch.observer/filing/0001213900-26-108467.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1505497/000121390026108467/0001213900-26-108467-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1505497/000121390026108467/ea0305784-8k_biore.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T15:11:44.946217+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3856530077","claim":"Katharyn Field resigned as Director at BioRestorative Therapies, Inc..","evidence_excerpt":"previously reported resignation of Katharyn Field as a director effective August 31, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1505497/000121390026108467/0001213900-26-108467-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6fbc6ac939","claim":"Donald J. Currie was appointed as Class I director at BioRestorative Therapies, Inc..","evidence_excerpt":"On October 7, 2026, the Board of Directors (the “ Board ”) of BioRestorative Therapies, Inc. (the “ Company ”) appointed Donald J. Currie as a Class I director of the Company, effective immediately, to fill the vacancy created by the previously reported resignation of Katharyn Field as a director effective August 31, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1505497/000121390026108467/0001213900-26-108467-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}